Novartis Spreads Cardiovascular Bets with Ionis Antisense Option Deal
Executive Summary
Further expanding its cardiovascular pipeline, Novartis has signed an option deal with Ionis – and invested $100m into the smaller company – to license two investigational antisense drugs targeting cardiovascular indications in patients with elevated levels of lipoprotein.
You may also be interested in...
Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease
Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.
Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
Quiet Riot? Gene Silencing Candidates Still Ready To Make Noise In Lipid Disorders
Despite complete response letter for Akcea's Waylivra, RNA therapeutics may have regulatory pathway to approval for lipid disorders.